Oramed Pharmaceuticals (PRNewsFoto/Oramed Pharmaceuticals Inc) Oramed Pharmaceuticals Inc.: Sufficient funds for clinical development activity over the next 24 months; several clinical milestones are scheduled for 2018 and 2019; as Oramed’s clinical progress meets our expectations, stock target price remains at NIS 53.2. jaimeuss_admin 6 בSeptember 2018 Research 0 Comments Continue Reading